Search for a clinical trial
Other search option(s)
8 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
FRANCE
ILE-DE-FRANCE
PARIS
A phase II study evaluating the efficacy and safety of lenalidomide (Revlimid®) with or without epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality - FR
CHU Paris Centre - Hôpital Cochin, Site Cochin
Service d'hématologie clinique
GERMANY
Baden-Württemberg
MANNHEIM
MDS-005: A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Lenalidomide versus Placebo in subjects with transfusion dependent Anemia due to low or intermediate risk MDS without Del 5Q and unresponsive to erythropoiesis-stimulating agents
Universitätsmedizin Mannheim
III. Medizinische Klinik
GERMANY
Nordrhein-Westfalen
DÜSSELDORF
Valena-Study: Phase II study for the determination of efficacy and tolerability of the combination of valproic acid and lenalidomide in the treatment of MDS patients with favorable risk profile - DE
Universitätstumorzentrum (UTZ)
Comprehensive Cancer Center (CCC) Düsseldorf
GERMANY
Sachsen
DRESDEN
A phase III, multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediate-1 risk Myelodysplastic Syndrome - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
SPAIN
Aragón
ZARAGOZA
A multicenter, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anaemic subjects with low or intermediante-1 risk myelodysplastic syndrome (MDS) - ES (Phase III) (Completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome - ES (Completed)
Institution: Information not provided - ES
ITALY
LIGURIA
GENOVA
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload - IT
Ospedali Galliera
S.S.D. Ematologia
ITALY
LOMBARDIA
MILANO